Modena (NASDAQ: MRNA) shares rose over 5% on Thursday after announcing it is developing a single-shot vaccine booster shot for both Covid-19 and the flu. According to a press release the new vaccine, named mRNA-1073, blends Moderna’s current Covid shot with one of its flu shots, which is also under development.
“Today we are announcing the first step in our novel respiratory vaccine program with the development of a single dose vaccine that combines a booster against COVID-19 and a booster against flu,” CEO Stephane Bancel said in a statement Thursday. “We are making progress on enrolling patients in our rare disease programs, and we are fully enrolled in our personalized cancer vaccine trial. We believe this is just the beginning of a new age of information-based medicines.”
The pharmaceutical company hopes to later release other vaccines it is working on for respiratory syncytial virus (RSV) and other respiratory diseases as an annual shot.
“We believe this is a very large opportunity that is ahead of us, if we could bring to market a high efficacy pan-respiratory annual booster,” Bancel said during a presentation to update investors on its drugs in development.
“We believe Moderna could be first to market in this important new opportunity,” he said.
Moderna is now conducting clinical trials for an RSV vaccine within older adults. Furthermore, the company is in mid-stage trial for its covid vaccine in children aged 6 months to less than 12 years.